TY - JOUR
T1 - Detection of plasmid-mediated class C β-lactamases
AU - Doi, Yohei
AU - Paterson, David L.
PY - 2007/5
Y1 - 2007/5
N2 - Plasmid-mediated class C β-lactamases are reported from Enterobacteriaceae with increasing frequency. They likely originate from chromosomal AmpC of certain Gram-negative bacterial species and subsequently are mobilized onto transmissible plasmids. There are reports of unfavorable clinical outcomes in patients infected with these organisms and treated with broad-spectrum cephalosporins. However, unlike class A extended-spectrum β-lactamases (ESBLs), no screening and confirmatory tests have been uniformly established for strains that produce class C β-lactamases. Reduced susceptibility to cefoxitin is a sensitive but not specific indicator of class C β-lactamase production. Simple confirmatory tests including tests using boronic acid compounds as specific class C β-lactamase inhibitors have recently been developed. Their utilization will enable clinical microbiology laboratories to report those strains producing plasmid-mediated class C β-lactamases as being resistant to all broad-spectrum cephalosporins, thus allowing physicians to prescribe appropriate antimicrobial therapy.
AB - Plasmid-mediated class C β-lactamases are reported from Enterobacteriaceae with increasing frequency. They likely originate from chromosomal AmpC of certain Gram-negative bacterial species and subsequently are mobilized onto transmissible plasmids. There are reports of unfavorable clinical outcomes in patients infected with these organisms and treated with broad-spectrum cephalosporins. However, unlike class A extended-spectrum β-lactamases (ESBLs), no screening and confirmatory tests have been uniformly established for strains that produce class C β-lactamases. Reduced susceptibility to cefoxitin is a sensitive but not specific indicator of class C β-lactamase production. Simple confirmatory tests including tests using boronic acid compounds as specific class C β-lactamase inhibitors have recently been developed. Their utilization will enable clinical microbiology laboratories to report those strains producing plasmid-mediated class C β-lactamases as being resistant to all broad-spectrum cephalosporins, thus allowing physicians to prescribe appropriate antimicrobial therapy.
UR - https://www.scopus.com/pages/publications/34247196603
UR - https://www.scopus.com/pages/publications/34247196603#tab=citedBy
U2 - 10.1016/j.ijid.2006.07.008
DO - 10.1016/j.ijid.2006.07.008
M3 - Review article
C2 - 17339123
AN - SCOPUS:34247196603
SN - 1201-9712
VL - 11
SP - 191
EP - 197
JO - International Journal of Infectious Diseases
JF - International Journal of Infectious Diseases
IS - 3
ER -